Gabapentin Tablet, Film Coated
Product Images NDC 71335-2719

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2719). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Creatinine Clearance (Gabapentin Fig1)

Creatinine Clearance (Gabapentin Fig1)
FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)
The text provides information on the Mean Pain Scores observed in Study 1 for the ITT Population. It includes data on Weekly Mean Pain Scores for the placebo group and the group receiving Gabapentin at a dose of 300 mg/day. However, due to the format and errors in text capture, the complete details and analysis of pain scores are not clearly comprehensible.*
FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)
FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)
FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)
This is a schedule illustrating the figure expressed as a difference from placebo by dose and study for adjunctive therapy in patients at 12 years of age with partial seizures. The graph shows the daily dose in milligrams ranging from 600 to 1800 over a period of time.*
FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical Structure (Gabapentin Str)
FDA Label Image

Label (Lbl713352719)

Label (Lbl713352719)
This is a product description for Gabapentin tablets, 600 mg. The tablets are film-coated and come in a child-resistant container. The recommended storage temperature is 20° to 25°C, with excursions permitted to 15° to 30°C. The tablets are available in packs of 90, and additional information can be found in the package insert by scanning the QR code. Manufacturing details include Bryant Ranch Prepack, Inc. and Aurobindo Pharma Limited.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.